ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Roma, Lazio

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Roma, Lazio, ITA:

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 125 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 213 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

Roma, RM, Italy and 92 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 176 other locations

to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian...

Enrolling
Peritoneal Neoplasms
Fallopian Tube Cancer
Drug: Nab-paclitaxel 80 mg/m^2
Drug: Relacorilant 150 mg once daily (QD)

Phase 2

Corcept Therapeutics
Corcept Therapeutics

Rome, Italy and 22 other locations

Locations recently updated

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Roma, Italy and 99 other locations

with either niraparib or lartesertib in participants with epithelial ovarian cancer. The participants will previously have progress...

Enrolling
Ovarian Cancer
Drug: Tuvusertib (M1774)
Drug: Lartesertib (M4076)

Phase 2

Merck KGaA (EMD Serono)
Merck KGaA (EMD Serono)

Rome, Italy and 57 other locations

in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...

Active, not recruiting
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 3

Mural Oncology

Rome, Italy and 118 other locations

of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study will ...

Enrolling
Recurrent Primary Peritoneal Cancer
Recurrent Ovarian Cancer
Drug: REGN4018
Drug: Sarilumab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Roma, Lazio, Italy and 53 other locations

. Solid ovarian masses have a risk of malignancy of 60%-75%2 and the discrimination between benign and malignant in this morphological categ ...

Enrolling
Ovarian Cancer
Diagnostic Test: RF data extraction
Institute of Hospitalization and Scientific Care (IRCCS)

Roma, Italy

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems